Price
Prices are end-of-day closes. This is a research view, the focus is on the fundamentals, quality and valuation below, not intraday price.
Smart Score
Above averageWe are a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines, the next frontier in innovative drug design aimed at improving treatment options for patients with cancer and inflammatory diseases. Powered by a fully artificial intelligence (AI)-integrated discovery engine capable of tackling any protein class, and coupled with leading ligase expertise, Nurix has built a significant advantage in translating the science of protein degradation into clinical advancements with the aim of establishing degrader-based treatments at the forefront of patient care.
In the company’s own words · 10-K filed Jan 28, 2026 · SEC EDGAR
Business segments
Q1 2026 · $36.3MThe company’s own SEC segment disclosure.
- License$30.0M83%
- Collaboration$6.3M17%
Nurix Therapeutics, Inc. (NRIX) reported revenue of $9.0M in Q2 2026 (quarter ended May 31, 2026), down 79% from the same quarter a year earlier. That came with net loss of $90M. For the full year FY2025, revenue was $84M (+54% year on year) and net income −$264M. Its largest product in 2026-Q1 was License at $30M, 83% of the disclosed total, just ahead of Collaboration at 17%.
Raw charts
8 series · TTMAs reported to the SEC, without any scoring.